StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $0.25 | $0.24 | -2.88% | 3.0M |
| 05-12 | $0.24 | $0.25 | +0.41% | 2.5M |
| 05-13 | $0.25 | $0.26 | +3.59% | 1.3M |
| 05-14 | $0.26 | $0.25 | -5.38% | 1.4M |
| 05-15 | $0.25 | $0.24 | -4.55% | 1.1M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2024 2024-12-31 |
|---|---|---|---|---|
Revenue | $500.00K | $500.00K | $500.00K | $0.00 |
Operating Income | $-40.11M | $-31.72M | $-21.70M | $-47.36M |
Net Income | $-41.88M | $-34.53M | $-14.62M | $-43.25M |
EPS (Diluted) | $-0.05 | $-0.04 | $-0.03 | $-0.06 |
Total Assets | $45.92M | $53.60M | $62.63M | $76.39M |
Total Liabilities | $5.00M | $7.00M | $8.45M | $15.42M |
Cash & Equivalents | $40.99M | $48.70M | $56.13M | $69.80M |
Free Cash Flow OCF − CapEx | $-30.99M | $-23.31M | $-16.00M | $-32.83M |
Shares Outstanding | 797.12M | 796.02M | 794.02M | 739.62M |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).